A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension.

Trial Profile

A Randomized, Placebo-controlled, Double Blind, 4-period, Cross-over Trial, to Study the Effects of Aliskiren, Hydrochlorothiazide and Moxonidine on Endothelial Dysfunction in Obesity Related Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Dec 2012

At a glance

  • Drugs Aliskiren (Primary) ; Hydrochlorothiazide; Moxonidine
  • Indications Hypertension; Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics
  • Acronyms TARGET
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Feb 2012 Actual patient number (32) added as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Actual end date (February 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top